Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubenimex in Pulmonary Arterial Hypertension
NCT02664558Phase 2Completed
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Apr 2016
- Primary completion
- Nov 2017
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ubenimex in pulmonary arterial hypertension (PAH), sponsored by Eiger BioPharmaceuticals, Inc.. Started Apr 2016; status: completed.
02
Drugs
ubenimex
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02664558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664558.